Champions Oncology (CSBR) vs Tenax Therapeutics (TENX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Champions Oncology (CSBR) has outperformed Tenax Therapeutics (TENX) over the past year, losing 23.0% versus a loss of 76.2%. Over five years, CSBR leads with a -50.6% price change compared with -99.9% for TENX. Tenax Therapeutics is the larger company by market cap ($69.6 million vs $69.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CSBR | TENX |
|---|---|---|
| Share price | $4.98 | $1.86 |
| Market cap | $69.31M | $69.61M |
| 1-day change | +2.05% | -2.62% |
| YTD return | -27.93% | -84.74% |
| 1-year return | -23.03% | -76.25% |
| 5-year return | -50.60% | -99.93% |
| Forward P/E | 49.80 | — |
| EPS (TTM) | $-0.07 | $-1.48 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.31 | $19.40 |
| 52-week low | $4.59 | $1.31 |
| Distance from 52-week high | -40.07% | -90.41% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +575.27% |
| Average volume | 11.33K | 5.46M |
| Shares outstanding | 13.92M | 37.42M |
| Employees | 214 | 14 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CSBR has outperformed TENX by 53.2 percentage points over the past year.
About Champions Oncology
CSBR stock →Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice through TumorGraft Technology Platform.
Healthcare · Biotechnology · 214 employees
About Tenax Therapeutics
TENX stock →Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
Healthcare · Biotechnology · 14 employees
CSBR vs TENX FAQ
Which is bigger, Champions Oncology or Tenax Therapeutics?
Tenax Therapeutics (TENX) is larger, with a market capitalization of $69.61M compared with $69.31M for Champions Oncology (CSBR).
Which stock has performed better over the past year, CSBR or TENX?
CSBR returned -23.03% over the past 12 months, compared with -76.25% for TENX (price return, excluding dividends). Past performance does not predict future results.
Are Champions Oncology and Tenax Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.